simendan has been researched along with natriuretic peptide, brain in 86 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 45 (52.33) | 29.6817 |
| 2010's | 34 (39.53) | 24.3611 |
| 2020's | 7 (8.14) | 2.80 |
| Authors | Studies |
|---|---|
| Young, JB | 1 |
| Gattis, WA; Gheorghiade, M; Jain, P; Klein, L; Massie, BM | 1 |
| Teerlink, JR | 2 |
| Ambrosi, P; Andréjak, M; Gayet, JL | 1 |
| Krum, H; Liew, D | 1 |
| Riggs, JM | 1 |
| Graham, CA | 1 |
| Adamopoulos, S; Degiannis, D; Iliodromitis, E; Kostakis, G; Kremastinos, DT; Kyrzopoulos, S; Parissis, JT; Rassias, J | 1 |
| Andreadou, I; Androulakis, A; Avgeropoulou, C; Demopoulou, M; Kallikazaros, I; Markantonis-Kyroudis, S; Missovoulos, P | 1 |
| Gegenhuber, A; Haltmayer, M; Mueller, T | 1 |
| Adamopoulos, S; Farmakis, D; Filippatos, G; Kremastinos, DT; Lekakis, J; Panou, F; Paraskevaidis, I; Parissis, JT; Venetsanou, K | 1 |
| Berger, R; Bojic, A; Huelsmann, M; Moertl, D; Pacher, R | 1 |
| Huang, SJ; McLean, AS; Nalos, M; Ting, I | 1 |
| Farmakis, D; Kremastinos, DT; Parissis, JT | 1 |
| McLachlan, CS; Mossop, P | 1 |
| Mehra, MR | 1 |
| Atar, D; Hodt, A; Steine, K | 1 |
| Böttiger, BW; Motsch, J; Rauch, H | 1 |
| Adamopoulos, S; Farmakis, D; Filippatos, GS; Gheorghiade, M; Iliodromitis, EK; Karatzas, D; Kremastinos, DT; Paraskevaidis, I; Parissis, JT; Tsiapras, D | 1 |
| Kivikko, M; Kupari, M; Laine, M; Lilleberg, J; Palkama, T; Pohjanjousi, P | 1 |
| Ahmadi, R; Berger, R; Bojic, A; Heissenberger, I; Huelsmann, M; Moertl, D; Pacher, R | 1 |
| Munger, MA | 1 |
| Giannakoulas, G; Giannoglou, G; Kalpidis, P; Louridas, G; Martiadou, K; Parharidis, G; Vassilikos, V | 1 |
| Adamopoulos, S; Farmakis, D; Filippatos, G; Iliodromitis, E; Kremastinos, DT; Panou, F; Paraskevaidis, I; Parissis, JT | 1 |
| Flevari, P; Kourea, K; Kremastinos, DT; Leftheriotis, D; Panou, F; Parissis, JT | 1 |
| Colucci, WS; Finckenberg, P; Haikala, H; Kaheinen, P; Kytö, V; Leskinen, H; Levijoki, J; Louhelainen, M; Merasto, S; Mervaala, EM; Pollesello, P; Vahtola, E | 1 |
| Cohen-Solal, A; Kivikko, M; Kleber, FX; Mebazaa, A; Nieminen, MS; Packer, M; Padley, RJ; Pocock, SJ; Põder, P; Thakkar, R | 1 |
| Arapi, S; Bistola, V; Farmakis, D; Filippatos, G; Karavidas, A; Korres, D; Kremastinos, DT; Matsakas, E; Paraskevaidis, IA; Parissis, JT | 1 |
| Yasumura, Y | 1 |
| Bistola, V; Farmakis, D; Filippatos, G; Kremastinos, D; Nikolaou, M; Papadopoulos, C; Paraskevaidis, I; Parissis, JT | 1 |
| Bunc, M; Vrtovec, B; Yazdanbakhsh, AP; Zemljic, G | 1 |
| Butler, J; Giamouzis, G; Giannakoulas, G | 1 |
| Ata, N; Birdane, A; Cavusoglu, Y; Demirustu, C; Gorenek, B; Tek, M; Timuralp, B; Unalir, A | 1 |
| Tang, WH | 1 |
| Best, M; Dembo, L; Driscoll, GO; Parle, NM; Thomas, MD | 1 |
| Böhm, M; De Luca, L; Dickstein, K; El-Banayosy, A; Filippatos, G; Gheorghiade, M; Mebazaa, A; Nieminen, M; Parissis, JT; Rhodes, A; Voors, AA; Zannad, F | 1 |
| Agha, SA; Butler, J; Georgiopoulou, V; Giamouzis, G; Giannakoulas, G; Kalogeropoulos, A; Karvounis, H; Tsarpalis, K | 1 |
| Celik, T; Iyisoy, A; Kardesoglu, E; Yuksel, UC | 1 |
| Francis, GS; Unzek, S | 1 |
| Bistola, V; Filippatos, G; Ikonomidis, I; Kremastinos, DT; Papadopoulos, C; Paraskevaidis, IA; Parissis, JT | 1 |
| Belenkov, Y; Cleland, JG; Eha, J; Kivikko, M; Nieminen, MS; Põder, P; Sarapohja, T | 1 |
| Bistola, V; Farmakis, D; Filippatos, G; Iliodromitis, EK; Kremastinos, DT; Paraskevaidis, IA; Parissis, JT | 1 |
| Mebazaa, A; Paraskevaidis, I; Parissis, JT; Rafouli-Stergiou, P | 1 |
| Cai, D; Cohen-Solal, A; Huang, B; Logeart, D; Mebazaa, A; Nieminen, MS | 1 |
| Cao, DX; Cao, MH; He, B; He, WX; Li, J; Peng, SL; Xia, SX; Xu, ZD; Yang, T; Zhao, YF | 1 |
| Andersson, B; Bergh, CH; Dahlström, U; Forfang, K; Kivikko, M; Sarapohja, T; Ullman, B; Wikström, G | 1 |
| Branzi, G; Ciambellotti, F; Facchini, M; Giglio, A; Malfatto, G; Parati, G; Revera, M; Rosa, FD; Villani, A | 1 |
| Batur, MK; Kurt, IH; Yavuzer, K | 1 |
| Fox, CJ; Kaye, AD; Liu, H; Zhang, S | 1 |
| Anastasiou-Nana, M; Bistola, V; Ikonomidis, I; Papadopoulos, C; Paraskevaidis, IA; Parissis, J; Stassinos, V | 1 |
| Bautista-Hernandez, V; Fynn-Thompson, F; Portela, F; Sanchez-Andres, A | 1 |
| Feola, M; Lombardo, E; Piccolo, S; Taglieri, C; Vallauri, P; Valle, R | 1 |
| Kantor, PF; Timberlake, K | 1 |
| Bakır, F; Berker, D; Cetin, M; Çetin, ZG; Ciçekçioğlu, H; Güler, S; Işık, S; Ozuğuz, U; Uçar, O | 1 |
| Bocchi, EA; Carvalho, VO; Cruz, F; Guimarães, GV; Issa, VS; Moura, LZ | 1 |
| Favilli, R; Focardi, M; Guarino, E; Lunghetti, S; Maffei, S; Mondillo, S; Palmerini, E; Urselli, R | 1 |
| Kilo, J; Schermer, E; Schweigmann, U; Velik-Salchner, C | 1 |
| Büyüklü, M; Kürüm, AT; Set, T; Tatlý, E | 1 |
| Aydoğdu, S; Cetin, M; Cicekçioğlu, H; Güven Cetin, Z; Sahin, M; Uçar, O; Vasfi Ulusoy, F | 1 |
| Branzi, G; Della Rosa, F; Facchini, M; Malfatto, G; Parati, G; Rella, V; Villani, A | 1 |
| Arkhipova, OA; Chazova, IE; Danilov, NM; Kobal', EA; Martyniuk, TV | 1 |
| Ambrosy, AP; Butler, J; Gheorghiade, M; Greene, SJ; Vaduganathan, M | 1 |
| Hou, ZQ; Hu, B; Shang, DY; Su, CY; Sun, ZX; Tan, H; Zhong, X; Zhou, Y | 1 |
| Acarturk, E; Bacaksiz, A; Bozkurt, A; Demir, M; Eker, RA; Kanadasi, M; Sahin, DY; Tasal, A; Vatankulu, MA | 1 |
| Blengino, S; Branzi, G; Della Rosa, F; Facchini, M; Giglio, A; Malfatto, G; Parati, G; Rella, V; Villani, A | 1 |
| Akturk, IF; Birant, A; Erturk, M; Karakurt, H; Kurtar Mansıroglu, A; Oner, E; Somuncu, MU; Uzun, F; Yalcin, AA; Yildirim, A | 1 |
| Chivite, D; Corbella, X; Formiga, F | 1 |
| Favilli, R; Lunghetti, S; Mondillo, S; Palmerini, E; Söderberg, S | 1 |
| Guo, M; Jia, Z; Liang, HQ; Song, Y; Zhang, LY; Zhang, YQ | 1 |
| Huang, J; Qian, J; Yao, Y; Zhang, D | 1 |
| Carriò, ML; Castro, MJ; Farrero, E; Javierre, C; Lopez-Delgado, JC; Periche, E; Pinseau, A; Rodríguez-Castro, D; Torrado, H; Toscano, JE; Ventura, JL | 1 |
| Akhtar, MS; Dhyani, N; Hassan, MQ; Ismail, MV; Najmi, AK; Pillai, KK | 1 |
| Hu, MH; Ji, CL; Lai, ZZ; Meng, JB; Tian, S; Xu, XJ; Zhang, G | 1 |
| Almenar, L; Blasco, T; Bruguera, J; Comín-Colet, J; Crespo-Leiro, MG; Delgado, J; García Pinilla, JM; Gonzalez-Vilchez, F; Grau, M; Lambert-Rodríguez, JL; Manito, N; Pascual-Figal, D; Segovia-Cubero, J; Sionis, A | 1 |
| Chen, D; Matter, A; Sivakumar, N; Teneggi, V | 1 |
| Bergounioux, J; Essid, A; Haegy, I; Josseran, L; Mbieleu, B; Sumanaru, D | 1 |
| Li, J; Li, Y; Wang, XY; Yang, F; Yang, J; Yang, ZY; Yuan, P | 1 |
| Al-Beidh, F; Antcliffe, DB; Ashby, D; Cross, M; Gordon, AC; Mason, AJ; McAuley, DF; O'Dea, K; Orme, RML; Perkins, GD; Santhakumaran, S; Singer, M; Ward, JK | 1 |
| Chen, Y; Cui, D; Li, G; Liao, Y | 1 |
| Chen, X; Lei, J; Liao, X; Qian, L; Zhang, S | 1 |
| Fu, M; Liu, Y; Wang, Z | 1 |
| Gruchała, M; Korościk, E; Lelonek, M; Stopczyńska, I; Straburzyńska-Migaj, E | 1 |
| Jun, M; Lan, L; Libiya, Z; Shubin, J; Xiangli, S | 1 |
| Adamowitsch, N; Berger, C; Clement, T; Fleischmann, E; Fraunschiel, M; Graf, A; Horvath, K; Kabon, B; Kuhrn, M; Reiterer, C; Taschner, A; Treskatsch, S | 1 |
| Lin, X; Liu, G | 1 |
24 review(s) available for simendan and natriuretic peptide, brain
| Article | Year |
|---|---|
New therapeutic choices in the management of acute congestive heart failure.
Topics: Acute Disease; Heart Failure; Humans; Hydrazones; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Pyridazines; Quinolones; Simendan; Treatment Outcome; Vasodilator Agents | 2001 |
Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization.
Topics: Aged; Diuretics; Dobutamine; Enalaprilat; Female; Heart Failure; Hemodynamics; Hospitalization; Humans; Hydrazones; Injections, Intravenous; Male; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Nitroprusside; Pulmonary Wedge Pressure; Pyridazines; Renal Agents; Simendan; Vasodilator Agents | 2003 |
Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure.
Topics: Acute Disease; Drug Approval; Dyspnea; Forecasting; Heart Failure; Hospitalization; Humans; Hydrazones; Natriuretic Agents; Natriuretic Peptide, Brain; Pyridazines; Pyridines; Randomized Controlled Trials as Topic; Severity of Illness Index; Simendan; Tetrazoles; Treatment Outcome; Vasodilator Agents | 2003 |
[The best of clinical pharmacology in 2002].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Azetidines; Cardiovascular Diseases; Ezetimibe; Hormone Replacement Therapy; Humans; Hydrazones; Hypercholesterolemia; Losartan; Myocardial Infarction; Natriuretic Agents; Natriuretic Peptide, Brain; Neovascularization, Physiologic; Nicorandil; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Vasodilator Agents | 2003 |
The development of new medical treatments for acute decompensated heart failure.
Topics: Acute Disease; Cardiotonic Agents; Cohort Studies; Heart Failure; Hemodynamics; Humans; Hydrazones; Multicenter Studies as Topic; Natriuretic Agents; Natriuretic Peptide, Brain; Placebos; Pyridazines; Pyridines; Randomized Controlled Trials as Topic; Receptors, Endothelin; Simendan; Tetrazoles; Time Factors; Vasodilator Agents | 2002 |
New and emerging drug therapies for the management of acute heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Heart Failure; Humans; Hydrazones; Natriuretic Agents; Natriuretic Peptide, Brain; Pyridazines; Pyridines; Simendan; Tetrazoles; Treatment Outcome; Vasodilator Agents; Vasopressins | 2003 |
New therapies for heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Diuretics; Drug Therapy, Combination; Eplerenone; Heart Failure; Humans; Hydrazones; Natriuretic Agents; Natriuretic Peptide, Brain; Neurotransmitter Agents; Pyridazines; Simendan; Spironolactone; Treatment Outcome; United States | 2004 |
Pharmacological therapy of acute cardiogenic pulmonary oedema in the emergency department.
Topics: Acute Disease; Analgesics, Opioid; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Critical Illness; Developed Countries; Diuretics; Emergency Service, Hospital; Emergency Treatment; Evidence-Based Medicine; Furosemide; Heart Failure; Humans; Hydrazones; Natriuretic Agents; Natriuretic Peptide, Brain; Nitroprusside; Oxygen Inhalation Therapy; Patient Selection; Pulmonary Edema; Pyridazines; Pyridines; Simendan; Tetrazoles; Treatment Outcome; Vasodilator Agents | 2004 |
Optimizing outcomes in the patient with acute decompensated heart failure.
Topics: Biomarkers; Cardiotonic Agents; Diuretics; Heart Failure; Hemodynamics; Humans; Hydrazones; Milrinone; Natriuretic Agents; Natriuretic Peptide, Brain; Nitroglycerin; Pyridazines; Pyridines; Risk Assessment; Simendan; Tetrazoles; Therapeutics; Troponin; Vasodilator Agents; Ventricular Function, Left; Ventricular Pressure | 2006 |
[Medical and ventilatory treatment of acute heart failure].
Topics: Acute Disease; Adrenergic beta-Agonists; Cardiotonic Agents; Continuous Positive Airway Pressure; Diuretics; Dobutamine; Furosemide; Heart Failure; Humans; Hydrazones; Isosorbide Dinitrate; Natriuretic Agents; Natriuretic Peptide, Brain; Nitric Oxide Donors; Oxygen Inhalation Therapy; Practice Guidelines as Topic; Pyridazines; Simendan; Vasodilator Agents | 2006 |
Newer approaches to the pharmacological management of heart failure.
Topics: Calcium Signaling; Cardiotonic Agents; Cardiovascular Agents; Endothelins; Enzyme Inhibitors; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Pyridazines; Pyridines; Simendan; Tetrazoles | 2006 |
[Levosimendan for treatment of heart failure].
Topics: Blood Pressure; Calcium; Cardiotonic Agents; Clinical Trials as Topic; Cytokines; Heart Failure; Heart Rate; Humans; Hydrazones; Inflammation Mediators; Natriuretic Peptide, Brain; Pyridazines; Shock, Cardiogenic; Simendan | 2007 |
Pharmacologic therapy for acute heart failure.
Topics: Antidiuretic Hormone Receptor Antagonists; Catecholamines; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Natriuretic Agents; Natriuretic Peptide, Brain; Natriuretic Peptides; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Sodium Potassium Chloride Symporter Inhibitors; Treatment Outcome; Vasodilator Agents | 2007 |
Overview of emerging pharmacologic agents for acute heart failure syndromes.
Topics: Adenosine; Cardiovascular Agents; Endothelin-1; Etiocholanolone; Heart Failure; Hemodynamics; Humans; Hydrazones; Natriuretic Peptide, Brain; Perhexiline; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Sodium-Potassium-Exchanging ATPase; Syndrome; Vasodilator Agents | 2008 |
Management of heart failure: a brief review and selected update.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cardiotonic Agents; Diuretics; Heart Failure; Hemofiltration; Humans; Hydrazones; Natriuretic Peptide, Brain; Pacemaker, Artificial; Pyridazines; Simendan; Tolvaptan; Vasodilator Agents | 2008 |
[Effect of levosimendan on B-type natriuretic peptide levels in patients with advanced heart failure: a meta-analysis].
Topics: Cardiotonic Agents; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Pyridazines; Simendan | 2009 |
Cardiovascular pharmacology: an update.
Topics: Animals; Cardiovascular Agents; Cardiovascular Diseases; Diastole; Heart Failure; Humans; Hydrazones; Muscle Contraction; Myofibrils; Natriuretic Peptide, Brain; Nicardipine; Pyridazines; Pyridines; Sarcomeres; Simendan; Urea | 2010 |
Current pharmacologic management of pediatric heart failure in congenital heart disease.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Child; Diuretics; Heart Defects, Congenital; Heart Failure; Hemodynamics; Humans; Hydrazones; Incidence; Natriuretic Peptide, Brain; Pyridazines; Simendan | 2011 |
The disconnect between phase II and phase III trials of drugs for heart failure.
Topics: Animals; Benzazepines; Cardiovascular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Patient Readmission; Patient Selection; Pyridazines; Pyridines; Risk Assessment; Risk Factors; Simendan; Tetrazoles; Time Factors; Tolvaptan; Treatment Outcome; Xanthines | 2013 |
[Organ-protection therapy. A new therapeutic approach for acute heart failure?].
Topics: Acute Disease; Amides; Benzazepines; Cardio-Renal Syndrome; Dobutamine; Fumarates; Heart Failure; Humans; Hydrazones; Inflammation; Kaplan-Meier Estimate; Multicenter Studies as Topic; Natriuretic Peptide, Brain; Prognosis; Pyridazines; Randomized Controlled Trials as Topic; Recombinant Proteins; Relaxin; Simendan; Therapies, Investigational; Tolvaptan | 2014 |
Drugs' development in acute heart failure: what went wrong?
Topics: Acute Disease; Cardiotonic Agents; Drug Approval; Drug Development; Heart Failure; Humans; Natriuretic Peptide, Brain; Simendan | 2018 |
Levosimendan Can Improve the Level of B-Type Natriuretic Peptide and the Left Ventricular Ejection Fraction of Patients with Advanced Heart Failure: A Meta-analysis of Randomized Controlled Trials.
Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Randomized Controlled Trials as Topic; Simendan; Stroke Volume; Ventricular Function, Left | 2021 |
Network Meta-Analysis of the Safety of Drug Therapy for Cardiogenic Shock.
Topics: Aged; Disease Progression; Dobutamine; Dopamine; Epinephrine; Female; Hemodynamics; Humans; Male; Middle Aged; Milrinone; Natriuretic Peptide, Brain; Network Meta-Analysis; Norepinephrine; Patient Safety; Recombinant Proteins; Shock, Cardiogenic; Simendan; Treatment Outcome | 2020 |
Effect of Levosimendan on B-type Natriuretic Peptide Levels in Patients with Heart Failure: A Systematic Review and Meta-Analysis.
Topics: Heart Failure; Humans; Natriuretic Peptide, Brain; Patients; Simendan | 2023 |
31 trial(s) available for simendan and natriuretic peptide, brain
| Article | Year |
|---|---|
The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine.
Topics: Adrenergic beta-Agonists; Aged; Aged, 80 and over; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Interleukin-6; Male; Malondialdehyde; Middle Aged; Natriuretic Peptide, Brain; Oxidative Stress; Pyridazines; Simendan; Time Factors; Tumor Necrosis Factor-alpha | 2005 |
Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure.
Topics: Aged; Cardiotonic Agents; Chi-Square Distribution; Echocardiography, Doppler; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Interleukin-6; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Simendan; Statistics, Nonparametric; Treatment Outcome; Ventricular Dysfunction, Left | 2005 |
Short-term effects of levosimendan and prostaglandin E1 on hemodynamic parameters and B-type natriuretic peptide levels in patients with decompensated chronic heart failure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alprostadil; Biomarkers; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Natriuretic Peptide, Brain; Phosphodiesterase Inhibitors; Prospective Studies; Pulmonary Wedge Pressure; Pyridazines; Simendan; Stroke Volume; Time Factors; Treatment Outcome; Vasodilator Agents | 2005 |
Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
Topics: Aged; Apoptosis; Cardiotonic Agents; Chronic Disease; Dobutamine; Echocardiography; Fas Ligand Protein; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Interleukin-6; Male; Membrane Glycoproteins; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Pulmonary Wedge Pressure; Pyridazines; Simendan; Stroke Volume; Treatment Outcome; Tumor Necrosis Factor-alpha; Tumor Necrosis Factors | 2006 |
Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure.
Topics: Atrial Natriuretic Factor; Cardiotonic Agents; Double-Blind Method; Echocardiography; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Placebos; Pulmonary Circulation; Pyridazines; Simendan; Systole; Time Factors; Ventricular Dysfunction, Left | 2007 |
Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure.
Topics: Adrenergic beta-Antagonists; Alprostadil; Cardiotonic Agents; Drug Interactions; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Prognosis; Pyridazines; Simendan; Stroke Volume; Vasodilator Agents | 2007 |
Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure.
Topics: Aged; Cardiomyopathies; Cardiotonic Agents; Cytokines; Electrocardiography; Female; Heart Failure; Humans; Hydrazones; Immunity, Cellular; Infusions, Intravenous; Male; Natriuretic Peptide, Brain; Peptide Fragments; Pyridazines; Simendan; Treatment Outcome; Troponin T; Vasodilator Agents; Ventricular Dysfunction, Left | 2006 |
Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Autonomic Nervous System; Cardiomyopathy, Dilated; Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Male; Natriuretic Peptide, Brain; Pyridazines; Simendan; Stroke Volume; Vasodilator Agents; Ventricular Dysfunction, Left | 2006 |
Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
Topics: Acute Disease; Aged; Cardiotonic Agents; Dobutamine; Double-Blind Method; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Simendan; Survival Analysis | 2007 |
Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure.
Topics: Aged; Chronic Disease; Endothelium, Vascular; Female; Heart Failure; Humans; Hydrazones; Intercellular Adhesion Molecule-1; Interleukin-6; Male; Middle Aged; Natriuretic Peptide, Brain; Nitroglycerin; Pyridazines; Severity of Illness Index; Simendan; Solubility; Stroke Volume; Vascular Cell Adhesion Molecule-1; Vasodilation; Vasodilator Agents | 2008 |
Effects of levosimendan on quality of life and emotional stress in advanced heart failure patients.
Topics: Aged; Cardiotonic Agents; Exercise Tolerance; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Length of Stay; Male; Middle Aged; Natriuretic Peptide, Brain; Psychometrics; Pyridazines; Quality of Life; Simendan; Stress, Psychological; Surveys and Questionnaires | 2007 |
Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation.
Topics: Biomarkers; Cardiotonic Agents; Creatinine; Female; Follow-Up Studies; Heart Failure; Heart Transplantation; Humans; Hydrazones; Infusions, Intravenous; Kidney; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyridazines; Simendan; Time Factors; Treatment Outcome; Waiting Lists | 2007 |
Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.
Topics: Adult; Aged; Ambulatory Care; Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyridazines; Simendan | 2008 |
Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
Topics: Aged; Biomarkers; Cardiotonic Agents; Chronic Disease; Disease Progression; Double-Blind Method; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Psychometrics; Pyridazines; Quality of Life; Severity of Illness Index; Simendan; Surveys and Questionnaires | 2008 |
Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure.
Topics: Acute Disease; Aged; Biomarkers; Cardiotonic Agents; Chronic Disease; Disease-Free Survival; Female; Follow-Up Studies; Heart Failure; Heart Function Tests; Humans; Hydrazones; Kaplan-Meier Estimate; Male; Middle Aged; Natriuretic Peptide, Brain; Patient Readmission; Predictive Value of Tests; Pyridazines; Sensitivity and Specificity; Simendan; Ultrasonography | 2010 |
Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Analysis of Variance; Antihypertensive Agents; Cardiotonic Agents; Confidence Intervals; Dobutamine; Double-Blind Method; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Male; Myocardial Perfusion Imaging; Natriuretic Peptide, Brain; Odds Ratio; Perfusion; Pulmonary Wedge Pressure; Pyridazines; Simendan; Vasodilator Agents | 2010 |
Acute effects of levosimendan on mitral regurgitation and diastolic function in patients with advanced chronic heart failure.
Topics: Aged; Cardiography, Impedance; Cardiotonic Agents; Chronic Disease; Diastole; Echocardiography, Doppler; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Italy; Male; Middle Aged; Mitral Valve Insufficiency; Natriuretic Peptide, Brain; Pilot Projects; Pyridazines; Severity of Illness Index; Simendan; Stroke Volume; Systole; Time Factors; Treatment Outcome; Vasodilator Agents; Ventricular Function, Left | 2010 |
Short-term effect of levosimendan on free light chain kappa and lambda levels in patients with decompensated chronic heart failure.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cardiotonic Agents; Chronic Disease; Down-Regulation; Female; Heart Failure; Humans; Hydrazones; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Severity of Illness Index; Simendan; Stroke Volume; Time Factors; Treatment Outcome; Turkey | 2010 |
Effects of levosimendan/furosemide infusion on plasma brain natriuretic peptide, echocardiographic parameters and cardiac output in end-stage heart failure patients.
Topics: Aged; Cardiac Output; Case-Control Studies; Echocardiography; Female; Follow-Up Studies; Furosemide; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Natriuretic Peptide, Brain; Pyridazines; Simendan; Time Factors | 2011 |
Effects of the recombinant form of the natural human B-type natriuretic peptide and levosimendan on pulmonary hyperventilation and chemosensivity in heart failure.
Topics: Adult; Brazil; Cardiovascular Agents; Chemoreceptor Cells; Chronic Disease; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Hypercapnia; Hyperventilation; Hypoxia; Infusions, Intravenous; Lung; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyridazines; Recombinant Proteins; Respiratory Rate; Simendan; Time Factors; Treatment Outcome | 2013 |
Intermittent levosimendan infusions in advanced heart failure: favourable effects on left ventricular function, neurohormonal balance, and one-year survival.
Topics: Aged; Calcium; Chronic Disease; Data Interpretation, Statistical; Diuretics; Drug Administration Schedule; Female; Furosemide; Heart Failure; Heart Function Tests; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Mortality; Natriuretic Peptide, Brain; Pyridazines; Severity of Illness Index; Simendan; Treatment Outcome; Ventricular Function | 2012 |
Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Biomarkers; Blood Pressure; Cardiotonic Agents; Chi-Square Distribution; China; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Failure; Heart Rate; Hospitalization; Humans; Hydrazones; Infusions, Intravenous; Kidney Diseases; Linear Models; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyridazines; Simendan; Stroke Volume; Time Factors; Treatment Outcome; Urination; Ventricular Function, Left | 2013 |
Comparison of single-dose and repeated levosimendan infusion in patients with acute exacerbation of advanced heart failure.
Topics: Aged; Biomarkers; Dose-Response Relationship, Drug; Echocardiography; Female; Heart Failure; Heart Ventricles; Humans; Hydrazones; Infusions, Intravenous; Interleukin-1beta; Interleukin-2; Interleukin-6; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Simendan; Tumor Necrosis Factor-alpha; Turkey; Vasodilator Agents | 2014 |
Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
Topics: Aged; Biomarkers; Cardiotonic Agents; Dobutamine; Echocardiography, Doppler; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Predictive Value of Tests; Pyridazines; Recovery of Function; Simendan; Stroke Volume; Systole; Time Factors; Treatment Outcome; Turkey; Ventricular Dysfunction, Left; Ventricular Function, Left | 2015 |
Levosimendan and nesiritide as a combination therapy in patients with acute heart failure.
Topics: Acute Disease; Aged; Aged, 80 and over; Cardiotonic Agents; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Mortality; Natriuretic Peptide, Brain; Patient Readmission; Pyridazines; Severity of Illness Index; Simendan; Treatment Outcome | 2015 |
Levosimendan Improves Clinical Outcomes of Refractory Heart Failure in Elderly Chinese Patients.
Topics: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Asian People; China; Creatinine; Female; Heart Failure; Humans; Hydrazones; Male; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Pyridazines; Simendan; Stroke Volume; Treatment Outcome | 2015 |
Levosimendan Versus Dobutamine in Myocardial Injury Patients with Septic Shock: A Randomized Controlled Trial.
Topics: Biomarkers; Demography; Dobutamine; Fatty Acid-Binding Proteins; Female; Hemodynamics; Humans; Hydrazones; Lactic Acid; Male; Middle Aged; Multivariate Analysis; Myocardium; Natriuretic Peptide, Brain; Pyridazines; Regression Analysis; Shock, Septic; Simendan; Troponin I; Ventricular Function, Left | 2016 |
Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial.
Topics: Aged; Cardiotonic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Injections, Intravenous; Male; Middle Aged; Natriuretic Peptide, Brain; Outpatients; Peptide Fragments; Protein Precursors; Retrospective Studies; Simendan; Stroke Volume; Treatment Outcome | 2018 |
Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial.
Topics: Aged; Biomarkers; Chemokine CCL2; Double-Blind Method; Female; Heart Diseases; HSP90 Heat-Shock Proteins; Humans; Intensive Care Units; Interleukin-10; Interleukin-6; Interleukin-8; Male; Middle Aged; Natriuretic Peptide, Brain; Organ Dysfunction Scores; Peptide Fragments; Prognosis; Shock, Septic; Simendan; Troponin I; United Kingdom | 2019 |
Effects of Xinkeshu combined with levosimendan on perioperative heart failure in oldest-old patients with hip fractures.
Topics: Aged; Aged, 80 and over; Drug Therapy, Combination; Drugs, Chinese Herbal; Endothelin-1; Female; Heart Failure; Hip Fractures; Humans; Male; Malondialdehyde; Natriuretic Peptide, Brain; Nitric Oxide; Simendan; Treatment Outcome | 2020 |
Effect of perioperative levosimendan administration on postoperative N-terminal pro-B-type natriuretic peptide concentration in patients with increased cardiovascular risk factors undergoing non-cardiac surgery: protocol for the double-blind, randomised,
Topics: Biomarkers; Cardiovascular Diseases; Heart Disease Risk Factors; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Simendan | 2022 |
31 other study(ies) available for simendan and natriuretic peptide, brain
| Article | Year |
|---|---|
Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients.
Topics: Aged; Cardiotonic Agents; Enzyme-Linked Immunosorbent Assay; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Interleukin-6; Male; Middle Aged; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Peptide Fragments; Pyridazines; Simendan | 2005 |
Levosimendan reduces plasma amino terminal proBNP in patients with decompensated heart failure.
Topics: Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Interleukin-6; Natriuretic Peptide, Brain; Peptide Fragments; Pyridazines; Simendan | 2005 |
Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Cardiotonic Agents; Echocardiography; Female; Heart Failure; Heart Rate; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Pyridazines; Simendan; Time Factors; Ventricular Function, Left | 2005 |
Levosimendan therapy in decompensated chronic heart failure: favourable haemodynamic and neurohormonal effects but for how long?
Topics: C-Reactive Protein; Cardiotonic Agents; Heart Failure; Hemodynamics; Humans; Hydrazones; Interleukin-6; Natriuretic Peptide, Brain; Pyridazines; Simendan; Time Factors; Treatment Outcome | 2006 |
Levosimendan and plasma BNP levels: do inflammatory cytokines regulate BNP in chronic decompensated heart failure?
Topics: Alprostadil; Biomarkers; Cardiotonic Agents; Chronic Disease; Cytokines; Dose-Response Relationship, Drug; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Pyridazines; Simendan; Stroke Volume; Vasodilator Agents | 2006 |
Management of acute decompensated heart failure: treatment, controversy, and future directions.
Topics: Acute Disease; Atrial Natriuretic Factor; Diuretics; Guideline Adherence; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Peptide Fragments; Practice Guidelines as Topic; Pyridazines; Randomized Controlled Trials as Topic; Simendan; Vasodilator Agents | 2006 |
Clinical significance of acute neurohormonal response after levosimendan treatment.
Topics: Aged; Cardiotonic Agents; Follow-Up Studies; Heart Failure; Humans; Hydrazones; Male; Natriuretic Peptide, Brain; Pyridazines; Simendan; Survival Rate; Treatment Outcome | 2006 |
Effects of levosimendan on cardiac remodeling and cardiomyocyte apoptosis in hypertensive Dahl/Rapp rats.
Topics: Animals; Apoptosis; Atrial Natriuretic Factor; Hydrazones; Hypertension; Male; Myocardium; Myocytes, Cardiac; Natriuretic Peptide, Brain; Norepinephrine; Osteopontin; Pyridazines; Rats; Rats, Inbred Dahl; RNA, Messenger; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; Sodium-Calcium Exchanger; Vasodilator Agents; Ventricular Remodeling | 2007 |
A struggle to SURVIVE: to abandon or not to abandon levosimendan?
Topics: Acute Disease; Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Pyridazines; Simendan; Survival Rate; Treatment Outcome | 2007 |
Both levosimendan and dobutamine treatments result in significant reduction of NT-proBNP levels, but levosimendan has better and prolonged neurohormonal effects than dobutamine.
Topics: Dobutamine; Humans; Hydrazones; Natriuretic Peptide, Brain; Neurotransmitter Agents; Peptide Fragments; Protein Precursors; Pyridazines; Simendan; Treatment Outcome | 2008 |
Natriuretic peptide-guided levosimendan therapy for heart failure: a promising new approach.
Topics: Adrenergic beta-Antagonists; Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Natriuretic Peptide, Brain; Predictive Value of Tests; Prognosis; Pyridazines; Simendan; Time Factors | 2008 |
The prolonged lowering effect of levosimendan on brain natriuretic peptide levels in patients with decompansated heart failure: clinical implications.
Topics: Cardiotonic Agents; Dobutamine; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Natriuretic Peptide, Brain; Predictive Value of Tests; Prognosis; Pyridazines; Simendan; Time Factors | 2008 |
Usefulness of dobutamine-induced changes of the two-dimensional longitudinal deformation predict clinical and neurohumoral improvement in men after levosimendan treatment in acutely decompensated chronic heart failure.
Topics: Aged; Cardiotonic Agents; Dobutamine; Echocardiography, Stress; Female; Heart Failure; Heart Ventricles; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Severity of Illness Index; Simendan; Stroke Volume | 2008 |
Levosimendan: from basic science to clinical practice.
Topics: Animals; Cardiotonic Agents; Coronary Circulation; Dobutamine; Heart Failure; Hemodynamics; Humans; Hydrazones; Kidney; Myocardial Contraction; Natriuretic Peptide, Brain; Prognosis; Pyridazines; Quality of Life; Simendan; Vasodilator Agents; Ventricular Dysfunction, Left; Ventricular Function, Right | 2009 |
Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
Topics: Aged; Cardiotonic Agents; Dobutamine; Female; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Randomized Controlled Trials as Topic; Retrospective Studies; Simendan | 2009 |
Dobutamine-induced changes of left atrial two-dimensional deformation predict clinical and neurohumoral improvement after levosimendan treatment in patients with acutely decompensated chronic heart failure.
Topics: Aged; Atrial Function, Left; Biomarkers; Chronic Disease; Dobutamine; Echocardiography; Echocardiography, Stress; Female; Forecasting; Heart Failure; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Neurotransmitter Agents; Pyridazines; Simendan; Treatment Outcome | 2012 |
Pharmacologic therapy of heart failure in children: part of a special series on paediatric pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathies; Cardiotonic Agents; Child; Digoxin; Diuretics; Heart Defects, Congenital; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Pyridazines; Simendan | 2011 |
Value of IGF-I levels in the evaluation of response to treatment with levosimendan in patients with severe heart failure.
Topics: Adult; Aged; Aged, 80 and over; Cardiotonic Agents; Cohort Studies; Female; Heart Failure; Humans; Hydrazones; Insulin-Like Growth Factor I; Male; Middle Aged; Natriuretic Peptide, Brain; Predictive Value of Tests; Prospective Studies; Pyridazines; Severity of Illness Index; Simendan; Treatment Outcome; Ultrasonography | 2011 |
Effects of levosimendan without loading dose on systolic and diastolic function in patients with end-stage heart failure.
Topics: Aged; Biomarkers; Cardiotonic Agents; Chi-Square Distribution; Diastole; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Italy; Male; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Severity of Illness Index; Simendan; Systole; Treatment Outcome; Ultrasonography; Ventricular Dysfunction, Left; Ventricular Function, Left | 2011 |
How mechanical circulatory support helps not to need it--new strategies in pediatric heart failure.
Topics: Adolescent; Cardiomyopathies; Cardiotonic Agents; Catecholamines; Child, Preschool; Extracorporeal Membrane Oxygenation; Female; Heart Failure; Humans; Hydrazones; Infant; Male; Milrinone; Myocarditis; Natriuretic Agents; Natriuretic Peptide, Brain; Pyridazines; Simendan | 2011 |
Effects of levosimendan on TNF-alpha, BNP and MMP-1 in patients with heart failure with anemia.
Topics: Aged; Anemia; Cardiotonic Agents; Chi-Square Distribution; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Matrix Metalloproteinase 1; Middle Aged; Natriuretic Peptide, Brain; Pyridazines; Simendan; Statistics, Nonparametric; Treatment Outcome; Tumor Necrosis Factor-alpha | 2012 |
The predictive value of QRS duration in response to levosimendan therapy in patients with decompensated heart failure.
Topics: Biomarkers; Cardiotonic Agents; Chi-Square Distribution; Echocardiography; Electrocardiography; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Natriuretic Peptide, Brain; Predictive Value of Tests; Pyridazines; Simendan; Statistics, Nonparametric; Systole; Treatment Outcome | 2012 |
[Possibilities of using levosimendan in patients with idiopathic pulmonary hypertension].
Topics: Adult; Blood Pressure; Cardiotonic Agents; Echocardiography; Epinephrine; Exercise Test; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Heart Rate; Humans; Hydrazones; Hypertension, Pulmonary; Infusions, Intravenous; Male; Natriuretic Peptide, Brain; Norepinephrine; Peptide Fragments; Pyridazines; Severity of Illness Index; Simendan; Ventricular Dysfunction, Right; Young Adult | 2012 |
Prognostic value of noninvasive hemodynamic evaluation of the acute effect of levosimendan in advanced heart failure.
Topics: Aged; Cardiac Catheterization; Cardiography, Impedance; Cardiotonic Agents; Feasibility Studies; Female; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Monitoring, Physiologic; Natriuretic Peptide, Brain; Neurotransmitter Agents; Prognosis; Pyridazines; Simendan | 2014 |
Effects of levosimendan on heart failure in normotensive patients: does loading dose matter?
Topics: Cardiotonic Agents; Drug Administration Schedule; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Infusions, Intravenous; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Pyridazines; Simendan; Ultrasonography; Vasodilator Agents | 2015 |
Five-year mortality in cardiac surgery patients with low cardiac output syndrome treated with levosimendan: prognostic evaluation of NT-proBNP and C-reactive protein.
Topics: Aged; C-Reactive Protein; Cardiac Output, Low; Cardiac Surgical Procedures; Cardiotonic Agents; Female; Follow-Up Studies; Humans; Hydrazones; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prognosis; Proportional Hazards Models; Prospective Studies; Pyridazines; Risk Factors; Simendan; Time Factors; Treatment Outcome | 2016 |
Levosimendan reduces myocardial damage and improves cardiodynamics in streptozotocin induced diabetic cardiomyopathy via SERCA2a/NCX1 pathway.
Topics: Animals; Body Weight; Cardiomyopathies; Cardiotonic Agents; Diabetes Mellitus, Experimental; Heart; Hemodynamics; Hydrazones; Male; Natriuretic Peptide, Brain; Nitric Oxide; Pyridazines; Rats; Rats, Wistar; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; Sodium-Calcium Exchanger; Streptozocin; Transforming Growth Factor beta; Troponin I | 2016 |
Levosimendan as Rescue Therapy for Acute Heart Failure in a Patient with Duchenne Muscular Dystrophy.
Topics: Acute Disease; Adult; Cardiomyopathies; Cardiotonic Agents; Heart Failure; Humans; Lactic Acid; Male; Muscular Dystrophy, Duchenne; Natriuretic Peptide, Brain; Pneumonia; Simendan | 2019 |
The efficacy of simendan in the treatment of acute heart failure and its impact on NT-proBNP.
Topics: Acute Disease; Aged; Aged, 80 and over; Calcium; Cardiotonic Agents; Female; Heart Failure; Humans; Hypokalemia; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Potassium; Simendan; Stroke Volume; Ventricular Function, Left | 2019 |
Multicenter experiences with levosimendan therapy and its safety in patients with decompensated advanced heart failure.
Topics: Cardiotonic Agents; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Poland; Prospective Studies; Simendan; Stroke Volume; Ventricular Function, Left | 2020 |
Effect of levosimendan combined with recombinant human brain natriuretic peptide on diuretic resistance.
Topics: Diuretics; Heart Failure; Heart Rate; Humans; Natriuretic Peptide, Brain; Simendan; Treatment Outcome | 2021 |